Ophthalmology Device Developer AmVision Bio Nets Tens of Mn of CNY in Series A

Healthcare Author: Manyu Zhang Editor: Yiru Qian Apr 26, 2022 11:30 PM (GMT+8)

The proceeds will be used to market and promote existing products, develop new products, and propel clinical trials along with applications of developed products.


AmVision Bio (Chinese:瑞泰生物) recently raised tens of millions of CNY in a Series A financing round led by HM Capital; Nanjing Ruiyuan and Guangzhou Industrial Investment are also involved.

Established in 2014 and headquartered in Guangzhou, AmVision Bio specializes in the research and development, production, and sales of related materials and medical devices in the field of ophthalmology regeneration medicine. 

The company launched the domestic first exclusive wet biological amniotic membrane in April 2020, which is able to solve various ophthalmic diseases from the ocular surface to the fundus. It can be applied in more than 15 fields, with ocular surface reconstruction being the most prominent application area.

 AmVision Bio has rich R&D pipelines with many products ready to enter the clinical stage, covering ocular surface damage, dry eye, glaucoma, fundus macular hole, optometry and other fields. Driven by the firm’s internal independent R&D capabilities, external global exploration BD capabilities, and a perfect R&D-product registration-marketing closed-loop system, AmVision Bio has now become a leading domestic innovative technology and service platform in the field of ophthalmic medical devices.

Dr. Lin Yongliang, the founder of AmVision Bio, has more than 15 years of experience in the research and development of implantable regenerative medical device products. Mr. Xu Hao, the co-founder of the company, leads an experienced sales team in the field of ophthalmology with strong product promotion capability, which is also one of the company's core competitiveness.

“Affected by the aging population, the demand for ophthalmic medical services is growing. Several products of AmVision Bio can fill the gap in the eye disease treatment market, and we look forward to seeing the development and implementation of more products,” said HM Capital.

The main competitors of AmVision Bio include Greenovo (NEEQ:871920), ZD Medical, Yeasn, Eyebright and 66Vision.